更名NovaBridge Biosciences,从“专注美国”转向亚太地区注资3700万美元成立眼科NewCo Visara计划收购VEGF-A/ANG2双特异融合蛋白VIS-101继续开发CLDN18.2x4-1BB双抗givastomig公司股价周五下跌20%,反映市场对战略不确定性的担忧在剥离中国业务成为专注美国市场的生物技术公司后不到两年后,I-Mab Biopharma再次公布新战略,...
Source Link更名NovaBridge Biosciences,从“专注美国”转向亚太地区注资3700万美元成立眼科NewCo Visara计划收购VEGF-A/ANG2双特异融合蛋白VIS-101继续开发CLDN18.2x4-1BB双抗givastomig公司股价周五下跌20%,反映市场对战略不确定性的担忧在剥离中国业务成为专注美国市场的生物技术公司后不到两年后,I-Mab Biopharma再次公布新战略,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.